Explore

Macrogen Launches Next-Generation Spatial Transcriptome Analysis Service in Asia

Macrogen Launches Next-Generation Spatial Transcriptome Analysis Service in Asia

Macrogen Launches Next-Generation Spatial Transcriptome Analysis Service in Asia

Illumina Inc. and Bruker Corporation Advance Spatial Omics Technology with New Offerings and Acquisitions

Illumina Inc. and Bruker Corporation Advance Spatial Omics Technology with New Offerings and Acquisitions

Illumina Inc. and Bruker Corporation Advance Spatial Omics Technology with New Offerings and Acquisitions

Molekula Details Strategies for Isotopically Labelled Nucleotide Supply Chain Resilience Amid Geopolitical Tensions

Molekula Details Strategies for Isotopically Labelled Nucleotide Supply Chain Resilience Amid Geopolitical Tensions

Molekula Details Strategies for Isotopically Labelled Nucleotide Supply Chain Resilience Amid Geopolitical Tensions

Indian Biotech Firm PopVax Advances Personalized mRNA Vaccines for Cancer Treatment with RNA Foundry Launch

Indian Biotech Firm PopVax Advances Personalized mRNA Vaccines for Cancer Treatment with RNA Foundry Launch

Hyderabad-based biotechnology firm PopVax has launched its RNA Foundry, a specialized facility dedicated to developing personalized cancer vaccines using messenger RNA (mRNA) technology. The company, backed by entities including the Gates Foundation, Ethereum co-founder Vitalik Buterin, the US government agency BARDA, and Facebook co-founder Dustin Moskovitz, aims to design and manufacture vaccines tailored to individual cancer patients. These vaccines will utilize genetic information obtained from tumor sequencing to train the immune system to recognize and attack cancer cells specific to each patient's mutations. This approach builds on the mRNA technology successfully used in COVID-19 vaccines, focusing on unique genetic targets within individual tumors.

Mount Sinai Health System Seeks Bioinformatician III for AI Human Health Research

Mount Sinai Health System Seeks Bioinformatician III for AI Human Health Research

The Mount Sinai Health System's Artificial Intelligence and Human Health Department is actively seeking a Bioinformatician III to join its expanding genomics and precision medicine research program. This role is designed for a highly motivated genetic epidemiologist or statistical geneticist who will be instrumental in leading and supporting analyses of extensive genomic, proteomic, multi-omics, and longitudinal clinical datasets. The successful candidate will apply advanced statistical genetics, bioinformatics, machine learning, and AI methodologies to uncover the biological underpinnings of complex and rare diseases. This position offers a unique opportunity to spearhead independent research projects, contribute to high-impact publications and grant applications, and collaborate within a multidisciplinary team at the forefront of human genetics and precision medicine. The role requires a minimum of six years of experience and proficiency in various computational tools and environments, including R, Pytho...

Machine Learning Uncovers Cell-Type Specific Alzheimer's Disease Programs

Machine Learning Uncovers Cell-Type Specific Alzheimer's Disease Programs

A new study utilizing single-cell machine learning has identified genetically anchored, cell-type specific programs related to Alzheimer's disease (AD). Researchers employed a supervised machine learning framework to predict AD status at the single-cell level, analyzing single-nucleus RNA-sequencing data from hundreds of donors. This approach revealed specific genes and pathways relevant to AD, including microglia-specific neuroinflammatory genes and genes involved in protein homeostasis and glycosylation across various cell types. The study also found that multiple identified candidates are already linked to existing pharmacologic compounds, such as EGFR and HSP90AA1, which have AD-relevant mechanisms. The research aimed to understand the molecular changes occurring in individual brain cells during the progression of Alzheimer's, providing a more granular view than previous studies.

myDNA and Gene by Gene Expand Global Genomics Network with New UK Laboratory

myDNA and Gene by Gene Expand Global Genomics Network with New UK Laboratory

myDNA and its laboratory operating company, Gene by Gene, have officially opened a new genomic laboratory in Glasgow, Scotland. This facility joins existing laboratories in Houston, Texas, and Melbourne, Australia, creating a three-continent network capable of processing over 1.5 million genetic samples annually. The expansion aims to meet the growing demand for accessible, high-quality genetic testing globally, supporting healthcare systems, pharmaceutical and biotechnology companies, research institutions, and consumer genomics businesses. Dr. Lior Rauchberger, CEO of myDNA and Gene by Gene, emphasized that this move is a significant step towards making advanced genetic knowledge accessible to millions, transforming healthcare by enabling precision medicine on a global scale. The Glasgow laboratory is situated within the Queen Elizabeth University Hospital campus, which also houses the University of Glasgow's Living Laboratory for Precision Medicine.

BioMarin Seeks Director, Corporate Counsel for Early Research Development to Bolster Legal Strategy

BioMarin Seeks Director, Corporate Counsel for Early Research Development to Bolster Legal Strategy

BioMarin Seeks Director, Corporate Counsel for Early Research Development to Bolster Legal Strategy

Sino Biopharmaceutical Licenses Six Oncology Programs to Boehringer Ingelheim in Multi-Billion Dollar Deal

Sino Biopharmaceutical Licenses Six Oncology Programs to Boehringer Ingelheim in Multi-Billion Dollar Deal

Sino Biopharmaceutical Licenses Six Oncology Programs to Boehringer Ingelheim in Multi-Billion Dollar Deal

Dr. Drew Weissman's Discoveries in mRNA Technology Lead to Nobel Prize and New Therapeutic Applications

Dr. Drew Weissman's Discoveries in mRNA Technology Lead to Nobel Prize and New Therapeutic Applications

Dr. Drew Weissman, an American physician and immunologist, was awarded the 2023 Nobel Prize in Physiology or Medicine alongside Katalin Karikó for their discoveries concerning RNA modifications that enabled effective mRNA vaccines against COVID-19. Weissman's career began with studies on HIV interactions with immune cells before he collaborated with Karikó in the late 1990s, leading to their seminal 2005 study on modified nucleosides and immune recognition. Their work continued, demonstrating the advantages of incorporating pseudouridine into mRNA for greater protein production and biological stability, and later addressing issues of double-stranded RNA contaminants. Beyond COVID-19, Weissman has contributed to research on mRNA Zika vaccines and a universal influenza vaccine. His work also extends to cell reprogramming, with studies using mRNA to generate temporary CAR T cells for cardiac fibrosis and delivering mRNA to hematopoietic stem cells for conditions like sickle-cell disease. He is a founding scie...

Pharmacogenomics Market Projected to Reach $15.98 Billion by 2030 Driven by AI and Precision Medicine

Pharmacogenomics Market Projected to Reach $15.98 Billion by 2030 Driven by AI and Precision Medicine

The pharmacogenomics market is experiencing rapid growth, with projections indicating it will reach $15.98 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.2%. This expansion is fueled by increasing investments in precision medicine, the growing adoption of AI-powered genomic analysis, and broader applications in oncology and cardiology. Key trends shaping the industry include personalized medicine adoption, genetic testing for drug selection, integration of pharmacogenomic data into clinical workflows, and the expansion of companion diagnostics. Major companies in this landscape include Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, and Thermo Fisher Scientific Inc. Recent strategic moves, such as Genomenon's acquisition of Boston Genetics in June 2023, aim to enhance genomic intelligence capabilities by merging AI platforms with expert genome curation. Innovations like PGxAI's Sirius model, launched in December 2024, are further transforming drug response prediction and man...

Alamar Biosciences and Nightingale Health Partner with UK Biobank to Identify Early Biomarkers for Neurodegenerative Diseases

Alamar Biosciences and Nightingale Health Partner with UK Biobank to Identify Early Biomarkers for Neurodegenerative Diseases

Alamar Biosciences and Nightingale Health have initiated a collaborative study with the UK Biobank to identify early blood biomarkers for neurodegenerative conditions, including Parkinson’s and Alzheimer’s disease. This project, named UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife, will analyze hundreds of proteins in 80,000 blood samples from UK Biobank participants. The study combines Alamar’s NULISA protein-detection technology, which can detect proteins at very low concentrations using antibodies and DNA-based signals, with Nightingale’s laboratory infrastructure and the UK Biobank’s extensive health data. The goal is to uncover early molecular signatures that could aid in predicting disease risk, improving diagnosis, and guiding future treatment strategies. The study is expected to conclude by the end of 2027, with the resulting data made accessible to approved researchers globally through the UK Biobank Research Analysis Platform.